Search research articles
Contact Us
Filters
Showing results (91-100 of 111) with videos related to
Page
of 12
Sort By:
Dermatology and Therapy
|
April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology
|
April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Psoriasis (Auckland, N.Z.)
|
September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy
|
June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
Marco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Dermatology and Therapy
|
February 19, 2026
Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE Study
Emanuele Trovato, Claudio Bonifati, Simone Ribero, et al.
Acta Dermato-Venereologica
|
April 27, 2021
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study
Antonio Costanzo, Filomena Russo, Marco Galluzzo, et al.
American Journal of Clinical Dermatology
|
February 24, 2025
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study
Francesco Leo, Michela Ortoncelli, Ruggero Cascio Ingurgio, et al.
Journal of Clinical Medicine
|
May 27, 2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
The Journal of Dermatological Treatment
|
February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Claudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Dermatology and Therapy
|
January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 111) with videos related to
Sort By:
Page
of 12
Dermatology and Therapy
|
April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology
|
April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Psoriasis (Auckland, N.Z.)
|
September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study
Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy
|
June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
Marco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Dermatology and Therapy
|
February 19, 2026
Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE Study
Emanuele Trovato, Claudio Bonifati, Simone Ribero, et al.
Acta Dermato-Venereologica
|
April 27, 2021
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study
Antonio Costanzo, Filomena Russo, Marco Galluzzo, et al.
American Journal of Clinical Dermatology
|
February 24, 2025
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study
Francesco Leo, Michela Ortoncelli, Ruggero Cascio Ingurgio, et al.
Journal of Clinical Medicine
|
May 27, 2023
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
The Journal of Dermatological Treatment
|
February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Claudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Dermatology and Therapy
|
January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
Page
of 12